Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Altimmune (ALT) Debt to Equity (2016 - 2025)

Altimmune (ALT) has disclosed Debt to Equity for 13 consecutive years, with $0.08 as the latest value for Q3 2025.

  • On a quarterly basis, Debt to Equity changed N/A to $0.08 in Q3 2025 year-over-year; TTM through Sep 2025 was $0.08, a N/A change, with the full-year FY2022 number at $0.02, down 34.74% from a year prior.
  • Debt to Equity was $0.08 for Q3 2025 at Altimmune, down from $0.09 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of $0.09 in Q2 2025 to a low of $0.01 in Q2 2021.
  • A 4-year average of $0.03 and a median of $0.02 in 2023 define the central range for Debt to Equity.
  • Biggest YoY gain for Debt to Equity was 368.0% in 2021; the steepest drop was 83.68% in 2021.
  • Altimmune's Debt to Equity stood at $0.04 in 2021, then tumbled by 34.74% to $0.02 in 2022, then increased by 15.78% to $0.03 in 2023, then skyrocketed by 171.9% to $0.08 in 2025.
  • Per Business Quant, the three most recent readings for ALT's Debt to Equity are $0.08 (Q3 2025), $0.09 (Q2 2025), and $0.03 (Q3 2023).